24 reports of this reaction
2.6% of all CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE reports
#4 most reported adverse reaction
ACUTE KIDNEY INJURY is the #4 most commonly reported adverse reaction for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, manufactured by Actavis Pharma, Inc.. There are 24 FDA adverse event reports linking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE to ACUTE KIDNEY INJURY. This represents approximately 2.6% of all 933 adverse event reports for this drug.
Patients taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a less commonly reported adverse event for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, but still significant enough to appear in the safety profile.
In addition to acute kidney injury, the following adverse reactions have been reported for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 24 FDA reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 2.6% of all adverse event reports for CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, making it a notable side effect.
If you experience acute kidney injury while taking CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.